| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18829509 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 109 journal articles in the PubMed database | Email to a friend | | |
| Arteaga CL, O'Neill A, Moulder SL, et al.
A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. [Journal Article]
Clin Cancer Res 2008 Oct 1; 14(19):6277-83.
Abstract | Full Citation | Find Related Articles | | Stemmler HJ, Kahlert S, Brudler O, et al.
High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. [Clinical Trial, Phase II, Journal Article, Multicenter Study]
Clin Oncol (R Coll Radiol) 2005 Dec; 17(8):630-5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Sawaki M, Ito Y, Tada K, et al.
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. [Journal Article]
Tumori 2004 Jan-Feb; 90(1):40-3.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Raff JP, Rajdev L, Malik U, et al.
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Clin Breast Cancer 2004 Feb; 4(6):420-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Burstein HJ, Harris LN, Marcom PK, et al.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. [Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study]
J Clin Oncol 2003 Aug 1; 21(15):2889-95.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Parihar R, Nadella P, Lewis A, et al.
A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. [Clinical Trial, Clinical Trial, Phase I, Journal Article]
Clin Cancer Res 2004 Aug 1; 10(15):5027-37.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Jahanzeb M, Mortimer JE, Yunus F, et al.
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. [Clinical Trial, Clinical Trial, Phase II, Journal Article]
Oncologist 2002; 7(5):410-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Nishimura R, Okumura Y, Arima N
Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. [Journal Article]
Breast Cancer 2008; 15(1):57-64.
Abstract | Full Citation | Find Related Articles | | Schaller G, Fuchs I, Gonsch T, et al.
Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes. [JOURNAL ARTICLE]
J Clin Oncol 2007 Jun 18.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
